🇺🇸 NBIX — Neurocrine Biosciences, Inc.

Salud Compra fuerte
← Volver

Precio actual

164,63 USD

Máx. histórico

185,50

99 días

Caída desde máximo

-11,25%

Rango 52 semanas

122,14 – 186,12

Variación hoy

+3,05%

Cierre anterior

159,76

Rango de hoy

158,66 – 165,86

Volumen hoy

1.507.456

Peor caída histórica

-97,21%

15/03/2006 → 12/11/2009

Recuperado en 2911 días

Volatilidad anualizada ⓘ

61,30%

Información
Nombre completo
Neurocrine Biosciences, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Drug Manufacturers - Specialty & Generic
Empleados
2.500
PER ⓘ
24,43 (puede no estar actualizado)
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
207,50 USD (puede no estar actualizado)
Primera cotización
23/05/1996
Precio actualizado
hace 20 horas
Sobre la empresa

Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
05/12/2001 49,95 50,59 48,80 49,69 -0,02% 3,58% 1.332.800
04/12/2001 47,80 49,94 47,79 49,70 +4,99% 4,50% 3.340.400
03/12/2001 47,45 48,48 46,65 47,34 -0,53% 3,86% 612.000
30/11/2001 47,92 48,15 47,00 47,59 -0,85% 2,40% 447.500
29/11/2001 45,70 48,50 45,15 48,00 +4,69% 7,33% 646.600
28/11/2001 44,42 46,72 44,00 45,85 +1,96% 6,12% 827.200
27/11/2001 48,00 48,62 44,65 44,97 -6,37% 8,27% 782.100
26/11/2001 48,20 48,37 47,40 48,03 +0,27% 2,01% 457.200
23/11/2001 47,74 48,90 47,25 47,90 -0,08% 3,46% 151.800
21/11/2001 45,50 48,20 45,34 47,94 +5,41% 6,29% 794.100
20/11/2001 43,90 46,20 43,33 45,48 +4,29% 6,54% 1.116.600
19/11/2001 41,66 44,07 41,50 43,61 +4,83% 6,17% 503.300
16/11/2001 41,97 42,28 40,95 41,60 -0,91% 3,17% 319.800
15/11/2001 42,30 43,99 41,14 41,98 -1,01% 6,74% 215.400
14/11/2001 42,74 43,04 42,00 42,41 -0,91% 2,43% 129.500
13/11/2001 41,64 43,42 41,27 42,80 -0,81% 5,16% 279.700
12/11/2001 40,97 43,15 40,20 43,15 +5,53% 7,20% 203.200
09/11/2001 40,70 41,20 40,30 40,89 -0,66% 2,21% 202.700
08/11/2001 40,84 41,69 40,60 41,16 +1,13% 2,67% 507.000
07/11/2001 41,07 42,35 40,00 40,70 -1,21% 5,72% 258.800
06/11/2001 40,70 41,38 39,90 41,20 +2,33% 3,64% 115.200
05/11/2001 41,11 41,64 40,11 40,26 +0,85% 3,72% 290.200
02/11/2001 43,42 43,65 39,86 39,92 -8,06% 8,73% 308.500
01/11/2001 42,00 43,52 41,76 43,42 +3,21% 4,19% 221.800
31/10/2001 42,45 43,26 42,06 42,07 +0,14% 2,83% 371.200
30/10/2001 42,38 43,10 40,92 42,01 -0,24% 5,14% 338.100
29/10/2001 44,36 44,97 41,90 42,11 -5,58% 6,92% 289.300
26/10/2001 40,34 45,11 40,22 44,60 +10,40% 12,12% 1.305.900
25/10/2001 38,74 42,00 37,79 40,40 +3,59% 10,87% 947.900
24/10/2001 39,29 39,29 38,20 39,00 -1,02% 2,77% 620.200